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Background: Chronic inflammation is known to play a role in pancreatic carcinogenesis. 
Registry-based epidemiologic studies suggest associations between chronic inflammatory 
intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). 
Methods: We examined the association between genomic regions (20 kb upstream and 
20 kb downstream) surrounding germline variants for Crohn’s disease, ulcerative colitis, 
inflammatory bowel disease (Crohn’s disease and ulcerative colitis combined) and celiac 
disease identified in published genome-wide association studies (GWAS) and PDAC risk 
in 8384 cases and 11955 controls of European descent using summary statistic GWAS 
data from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer 
Case Control Consortium (PanC4). We employed the summary adaptive rank truncated 
product (sARTP) method to test the overall association of the combined genomic regions 
for each respective disease.  
Results: Categorization of the genomic regions for ulcerative colitis, Crohn’s disease, 
and inflammatory bowel disease were associated with PDAC at P-values < 0.05 (0.0030, 
0.037, and 0.0018, respectively). After excluding the regions around the previously 
identified GWAS loci for PDAC (500 kb upstream and 500 kb downstream), only the 
inflammatory bowel disease genomic regions remained borderline significantly 
associated with PDAC (P-value = 0.047). The top genes contributing to the inflammatory 
bowel disease association after excluding the regions around known PDAC GWAS 
signals were ACTR2 and LINC00339 (P-value < 0.001). Genomic regions for celiac 
disease were not associated with PDAC (P-value=0.31).  
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Conclusions: Our results from a large consortium provide modest support for the 
hypothesis that genomic regions surrounding germline risk variants for gastrointestinal 
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Pancreatic cancer is widely known for its increasing annual incidence and poor 
prognosis. 1 As of 2018, it is estimated that 55,440 people will be diagnosed with 
pancreatic cancer and 44,330 people will die of this disease, making it the 11th most 
common cancer type and the 3rd leading cause of cancer-related mortality in the United 
States. 1,2 Pancreatic ductal adenocarcinoma (PDAC) is the most common type of 
pancreatic cancer. 3 Effective, population-level screenings are not currently available for 
early disease diagnosis and management. 4 In addition to modifiable risk factors, such as 
cigarette smoking, and overweight and obesity, genetic susceptibility also contributes to 
risk, accounting for 5-10% of incident pancreatic cancer cases. 5-9 
Chronic gastrointestinal inflammation plays an important role in PDAC. 
Inflammatory bowel disease (IBD) patients have a high prevalence of pancreatic 
abnormalities, specifically idiopathic chronic pancreatitis. 10-13. Swedish registry-based 
studies have identified significant excess incidence of PDAC among patients with 
Crohn’s disease and ulcerative colitis (together known as IBD), compared to the general 
Swedish population, albeit based on a relatively small PDAC case numbers. 14,15 Celiac 
disease, which is characterized by chronic inflammation in small intestine, has been 
variably associated with PDAC. 16-18 A limitation of these studies is that chronic 
inflammatory intestinal diseases may not be clinically diagnosed, especially for those 
with mild symptoms. Therefore, the diseases may be underestimated in the epidemiologic 
studies that rely upon self-reported questionnaire or review of medical records. 
Association studies have suggested a genetic component underlying both IBD and celiac 
disease. 19-26  
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In this study, we examined the association between genomic regions (20 kb 
upstream and 20 kb downstream) surrounding germline variants identified from 
published genome-wide association studies (GWAS) of inflammatory bowel disease and 
celiac disease, and risk of PDAC among a total of 8384 PDAC cases and 11955 controls 
from the Pancreatic Cancer Cohort Consortium (PanScan) and Pancreatic Cancer Case-
Control Consortium (PanC4). 5,6,8,9 Our aim was to use genomic regions surrounding 
genetic variants that characterize these gastrointestinal inflammatory diseases as proxies 













2.1. Study sample 
Our study was based on 9038 PDAC cases and 12389 controls of European 
ancestry from four previously conducted GWASs in PanScan and PanC4. 5,6,8,9 The 
methods for each of the four GWASs have previously been described. 5,6,8,9 Participants 
with non-exocrine pancreatic tumors (histology types 8150, 8151, 8153, 8155 and 8240) 
were not included because the etiology of these cancer is thought to be different. To 
facilitate testing of interactions by study design (cohort verse case-control), we excluded 
654 cases and 434 controls derived from PanScan Ⅲ case series or case-control studies 
because PanScan Ⅲ used previously genotyped controls from cohort studies. We only 
included participants of European genetic ancestry to avoid the potential confounding due 
to population stratification. In total, 8384 PDAC cases and 11955 controls were included 
in our final analytic data set. 
All participants gave informed consent and all studies were approved by the 
Institutional Review Board of each participating institution and the National Cancer 
Institute’s Special Studies Institutional Review Board. 
2.2. GWAS summary statistics 
 Genotype imputation across the four study phases was based on the 1000G 
(Phase 3, v1) reference dataset. 27 Due to the large overlap of variants on the arrays 
(Illumina HumanHap550 Infinium II, Human 610-Quad) used for PanScan I and II, these 
studies were combined and jointly analyzed, whereas PanScan III (OmniExpress, 
Omni1M, Omni2.5M and Omni5M) and PanC4 (Illumina HumanOmniExpressExome-
8v1) were each analyzed separately. For each GWAS phase, unconditional logistic 
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regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI), 
adjusting for age (10-year categories, (≤50, 51-60, 61-70, 71-80, and ≥81)), sex, study, 
geographic region, and the top eigenvectors. Summary statistics for each of the phases 
were generated and used for analysis. 
2.3. SNPs selection 
We identified single-nucleotide polymorphisms (SNPs) associated with Crohn’s 
disease, ulcerative colitis, IBD (Crohn’s disease and ulcerative colitis combined) and 
celiac disease at genome-wide association level (P-value < 5×10-8) using the most recent 
and largest studies curated by NHGRI-EBI Catalog of published GWAS 
(https://www.ebi.ac.uk/gwas/) as of June 9, 2017. 19-26,28-41 We also reviewed each of the 
original GWAS publications and added additional SNPs that met the significance level 
criteria. 26 For each disease group, we mapped each germline variant to its closest gene 
and extended the genomic region 20 kb upstream and 20 kb downstream. We included 
genomic regions (50 kb upstream and 50 kb downstream) surrounding germline variants 
that do not map to any surrounding gene. 
2.4. Statistical analysis 
We employed the summary based adaptive rank truncated product (sARTP) 
method to test the association of the combined genomic regions for Crohn’s disease, 
ulcerative colitis, IBD and celiac disease with PDAC. The sARTP method combines 
SNP-level association statistics across SNPs in a gene or inflammatory gastrointestinal 
disease group. 42 The associations from up to five most significant SNPs in a gene were 
accumulated. To control for false positives, the sARTP method employed a resampling 
procedure to adjust for the size of genes (i.e., number of known SNPs in a gene) and the 
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size of genes in each disease group. The gene- and disease-level association P-values 
were estimated from the resampled null distribution using one hundred million 
resampling steps. A panel of 503 European subjects (CEU, TSI, FIN, GBR, IBS) in the 
1000 Genomes Project (phase 3, v1) was used in sARTP to estimate the linkage 
disequilibrium (LD) between SNPs. To eliminate the impact of population stratification, 
the square root of the genomic inflation factors for each study phase (𝜆 = 1.02, 1.02, 1.01 
and 1.06 for PanC4, PanScan I and II case-control, PanScan I and II cohort, and PanScan 
III cohort, respectively) was adjusted to rescale the standard error of the estimated log 
odds ratio at each SNP. To identify disease group associations not driven by GWAS 
signals, sensitivity analysis was performed by excluding the 1000-kb genomic region 
(500 kb upstream and 500 kb downstream) flanking the 21 previously published GWAS 
PDAC risk signals that could be caused by LD. These included signals at 1p36.33 
(NOC2L), 1q32.1 (NR5A2), 2p13.3 (ETAA1), 3q29 (TP63), 5p15.33 (CLPTM1L-TERT), 
7p13 (SUGCT), 8q21.11 (HNF4G), 8q24.21 (MYC), 7q32.3 (LINC-PINT), 9q34.2 (ABO), 
13q12.2 (PDX1), 13q22.1 (KLF5/KLF12), 16q23.1 (BCAR1), 17q12 (HNF1B), 17q25.1 










The proportion of cases diagnosed at ages older than 60 years was 0.74 overall.  A 
larger proportion of cases from the cohort studies were diagnosed at ages > 60 years 
compared to those from the case-control studies (Table 1).   
3.1. Disease group and PDAC 
The genomic regions for IBD (P-value = 0.0018), ulcerative colitis (P-value = 
0.0030) and Crohn’s disease (P-value = 0.037) were significantly associated with PDAC 
risk (Table 2). Genomic regions for celiac disease were not associated with PDAC (P-
value = 0.31). After excluding the 1000-kb genomic region around the previously 
identified PDAC GWAS signals, only the association for IBD remained nominally 
significant (P-value = 0.047). Ulcerative colitis and Crohn’s disease were no longer 
significantly associated with the outcome (P-value = 0.11 and 0.079, respectively). In 
stratified analyses by study design, the associations of genomic regions for IBD and 
ulcerative colitis with PDAC were statistically significant (P-value = 0.0094 and 0.0055, 
respectively) in case-control studies, but not in the cohort studies (P-value = 0.44 and 
0.84, respectively) (Supplemental Table 1). Neither Crohn’s nor celiac disease were 
significantly associated with PDAC in cohort and case-control studies. 
3.2. Gene and PDAC 
We computed gene-level P-values for the 382 genes included in the study (Table 
3). 27 genes for IBD, 15 genes for ulcerative colitis, 18 genes for Crohn’s disease, and 4 
genes for celiac disease had P-values < 0.05. The most significant genes contributing to 
each disease group included NR5A2, ACTR2, LINC00339 and TMEM8C for IBD; 
NR5A2, LINC00339 and TMEM8C for ulcerative colitis and ACTR2 and TMEM8C for 
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Crohn’s disease at a P-value < 0.001. After excluding previously identified PDAC 
GWAS loci, the most significant genes associated with each inflammatory disease group 
at a P-value < 0.001 were ACTR2 and LINC00339 for IBD; LINC00339 for ulcerative 
colitis and ACTR2 for Crohn’s disease (Supplemental Table 2).  
3.3. SNP and PDAC 
The association between individual SNP and PDAC within each gene that were 
significant at a P-value < 0.001 for each gastrointestinal disease group is shown in Table 
4. 34 SNPs located in 16 genes within the IBD pathway, 17 SNPs in 7 genes within the 
ulcerative colitis pathway, and 21 SNPs in 10 genes within the Crohn’s disease pathway 
were significantly associated with PDAC at a P-value < 0.001. Among the SNPs, 1 
(rs2816950) was located in the NR5A2 gene, 3 (rs268871, rs56792073, rs72822420) in 
ACTR2, 4 (rs3820290, rs140356857, rs60189068, rs2501299) in LINC00339 and 5 
(rs3094325, rs9331726, rs9330459, rs13293068, rs9286382) in TMEM8C. The D´ and r2 
between the susceptible locus for IBD (rs2816958) and the susceptible locus for PDAC 
(rs2816950) in the NR5A2 among European population were 0.06 and 0.001, respectively 








This pathway-based analysis of GWAS data showed that germline variations in 
the vicinity of susceptibility loci for gastrointestinal inflammatory diseases were 
significantly associated with PDAC. This association was attributed to the combined 
effect of germline variants located in NR5A2, ACTR2, LINC00339 and TMEM8C. 
Associations were more statistically significant in the case-control studies than in the 
cohort studies. Removal of previously identified PDAC-associated genetic variants 
resulted in the loss of significant association of the ulcerative colitis and Crohn’s disease 
group genomic regions, but the association between IBD and PDAC became borderline 
significant. TMEM8C was not significantly associated with PDAC after previously 
identified GWAS PDAC risk signals were excluded. We did not see an association 
between celiac disease and PDAC. 
The significant association between IBD, ulcerative colitis and Crohn’s disease 
pathway and PDAC is mainly driven by NR5A2, in which susceptible loci for both IBD 
and PDAC are located. 8,26 NR5A2, also known as liver receptor homolog (LRH-1), is an 
orphan nuclear receptor that is predominantly expressed in tissues of endodermal origin 
in mammals, such as the liver, exocrine pancreas and intestine. 45 NR5A2 shows 
pleiotropic effects and participates in a wide range of cellular processes. 46,47 Contrary to 
the role of NR5A2 in reverse cholesterol transport and bile acid homeostasis in liver, 48-56 
emerging evidence has revealed NR5A2 as a key player in the pathogenesis of IBD and 
PDAC. 47,57 NR5A2 regulates intestinal immunity and attenuates the inflammation 
response by upregulating the local production of glucocorticoids. 58 Coste et al. showed 
that haploinsufficency of Nr5a2 not only made mice more susceptible to developing IBD, 
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but also reduced the synthesis of glucocorticoids in intestine. 59 Consistent with the 
finding in the experimental mouse model, this study also identified reduced expression of 
NR5A2 in the colon tissues of IBD patients. 59 Elevated expression of NR5A2 in 
pancreatic ductal epithelium is associated with aggressive growth and proliferation of 
cancer cells in pancreas. 57,60,61 Benod et al. observed that the NR5A2 mRNA transcript 
was increased 30-fold in human pancreatic cancer cells as opposed to normal pancreatic 
ductal epithelial cells. 57 In the same study, small interfering RNA (siRNA)-mediated 
knockdown of NR5A2 substantially inhibited proliferation of pancreatic cells, 57 
suggesting that activated NR5A2 could result in pancreatic tumorigenesis. This 
hypothesis is supported by the established mechanisms of NR5A2 in the regulation of 
cell cycle, maintenance of pluripotent stem cells, and reprogramming of somatic cells. 
47,57,62-66 Another possible mechanism is implied in the protective effect of NR5A2 
against stress-induced apoptosis in pancreatic β cells via upregulating glucocorticoids 
synthesis. 67 However, it is unclear whether similar anti-apoptotic protection will be 
observed in the exocrine pancreas. 
Genetic variants within ACTR2, LINC00339 and TMEM8C in proximity to the 
IBD risk loci also contributed to the association between IBD and PDAC. Actin-related 
protein 2 (ARP2) encoded by ACTR2 in humans, is a major subunit of ARP2/3 complex. 
68 Although the function of ARP2 is yet to be determined, ARP2/3 complex has been 
shown to regulates actin cytoskeleton dynamics by participating in the assembly, 
organization and recycling of actin filaments. 69-75 Common cellular functions performed 
by ARP2/3 complex include cell migration, adhesion, and vesicle trafficking. 68,71-73,75-90 
Recent studies indicate that defective function of either ARP2/3 complex or its activator 
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Wiskott–Aldrich syndrome protein (WASP) is associated with IBD and other 
autoimmune adverse events. 71,91-96 On the other hand, excess of ARP2/3 complex may 
render cells additional capacity to invade surrounding tissues, 97 a property often seen in 
cancer metastasis. 98 Accumulating evidence supports that expression of the ARP2/3 
complex, together with WASP, is significantly upregulated in multiple tumor types, 
including pancreas. 99-104 The function of LINC00339 and TMEM8C is poorly 
understood in humans, and their biological links to both IBD and PDAC remain to be 
elucidated. One interesting observation that should be discussed here is that in the 
sensitivity analysis, the association between TMEM8C and PDAC in IBD, ulcerative 
colitis and Crohn’s disease group completely disappeared after removing 21 previously 
identified GWAS hits for PDAC. In contrast, the association of both ACTR2 and 
LINC00339 remained intact. One hypothesis is that SNPs in TMEM8C could be in LD 
with GWAS risk signals for PDAC. In fact, both TMEM8C and ABO are located on 
chromosome 9. 5 However, the five SNPs identified in TMEM8C are poorly correlated 
with the GWAS hit in ABO (http://archive.broadinstitute.org/mpg/snap/ldsearchpw.php). 
44 It could also be that NR5A2 and one of the PDAC risk genes might act sequentially in 
the same biological pathway, in which the risk gene is an upstream regulator of 
TMEM8C. Alternatively, it is possible that both NR5A2 and the risk gene might be 
independently governed by the same biological process, which could be disturbed if the 
risk gene is removed. 
Of note, the significant association of ulcerative colitis was lost after previously 
identified PDAC-associated genetic variants were removed. One of the known PDAC 
GWAS signal in the NR5A2, rs2816938, is highly correlated with the susceptible locus 
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for PDAC identified in this study, rs2816950. We suspect that removal of rs2816938 in 
the sensitivity analysis also eliminates the effect of rs2816950, resulting in non-
significant association between ulcerative colitis and PDAC. We observed more 
significant associations for ulcerative colitis and IBD among the case-control studies 
compared to cohort studies (Supplemental table 1).  We speculate that this is mostly 
likely due to the larger number of cases and controls from the case-control studies and 
power to observe associations.  Alternatively, the differences might be due to biases 
related to the selection of either the cases (e.g. survival bias) or controls from the case-
control studies. 
A strength of our study is its large number of PDAC cases and controls with 
genomewide genetic data and the ability to control for several confounding factors. Our 
findings should be interpreted cautiously considering several limitations. We lack direct 
clinical examination and diagnosis of these diseases and information on important 
environmental factors (e.g. gluten exposure) that play a role in the etiology of these 
diseases. Our associations are based on genomic regions identified from GWAS studies 
associated with Crohn’s, ulcerative colitis, and celiac disease, which provides the 
opportunity to validly identify susceptibility to chronic inflammatory intestinal diseases 
and PDAC risk, even for those with IBD or celiac disease who may not be diagnosed. We 
employ statistical-based method to account for the cumulative effects of multiple SNPs 
associated with each disease group to evaluate genetic susceptibility for PDAC. 42,105-107 
This inter-SNP interaction commonly seen in complex traits is overlooked in GWAS 
where the association of single SNP is tested independently, 40,108,109 resulting in “missing 
heritability”. 110 Nevertheless, one limitation of this pathway approach is that it only 
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includes genomewide significant SNPs into analysis. Given that heritability is often 
distributed over thousands of genetic variants with small effects in complex traits, 111,112 
the present study may overlook a significant portion of heritability. A complementary 
approach to investigate genetic overlap across diseases is LD Score regression, 111,113 
which take the effect of all SNPs into account, regardless of their genomewide 
significance level. Our study may not be generalizable to non-European ancestry 
populations.   
In summary, this study employed sARTP method to assess genetic susceptibility 
to inflammatory intestinal diseases in relation to risk of PDAC. Our results provide 
modest support for the hypothesis that genomic regions flanking GWAS-identified 
germline variants for inflammatory bowel diseases but not celiac disease are associated 
with PDAC. These findings may help better understand the etiology of PDAC. Further 
investigations are warranted to replicate our findings and to examine such associations in 
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 Table 1. Baseline Characteristics of Participants From PanScan and PanC4 Studies 
Phase Study design Cases, n Controls, n 
Case diagnosis age > 60 
(%) 
PanScan Ⅰ 
Cohort 1383 1470 83.44 
Case-control 363 342 73.00 
PanScan Ⅱ Case-control 1768 1841 66.06 
PanScan Ⅲ Cohort 937 4651 93.92 
PanC4 Case-control 3933 3651 69.70 
Total Cohort 2320 6121 87.67 
 Case-control 6064 5834 68.83 























Table 2. Association a of Inflammatory Gastrointestinal Disease Groups and Risk of 
PDAC in PanScan and PanC4 Studies 
Disease group Gene, n SNPs, n P-value 
Ulcerative colitis 163 13,522 0.0030 
Crohn’s disease 266 21,034 0.037 
IBD 353 26,574 0.0018 
Celiac disease 40 3,617 0.31 
Excluding previous PDAC GWAS loci b 
Ulcerative colitis 156 12,925 0.11 
Crohn’s disease 262 20,521 0.079 
IBD 344 25,860 0.047 
Celiac disease 40 3,544 0.31 
a The analysis was adjusted for age, sex, study, geographic region, and the top eigenvectors. 






















Table 3. Association a of Inflammatory Gastrointestinal Disease Genes and Risk of 
PDAC at a P < 0.05 in PanScan and PanC4 Studies 
Disease group Gene SNPs, n P-value 
Most significant 
SNP 
IBD NR5A2 129 1.0 × 10-7 rs2816950 
ACTR2 30 2.3 × 10-4 rs268871 
LINC00339 48 3.2 × 10-4 rs3820290 
TMEM8C 99 6.0 × 10-4 rs3094325 
RP11-594C13.1 147 0.0034 rs76145598 
rs1991866 b 59 0.0038 rs1372993 
AC007318.5 14 0.0071 rs6741232 
AZU1P1 20 0.0076 rs9548954 
COG6 83 0.0082 rs9532431 
NF2 50 0.012 rs9613968 
PPP3CA 129 0.014 rs756317 
CUX2 117 0.014 rs4766453 
F5 50 0.015 rs34067653 
FERMT1 107 0.016 rs11699483 
GS1-259H13.10 23 0.017 rs78680379 
ACER3 69 0.019 rs61902094 
RP11-213G21.2 43 0.019 rs80095830 
RP11-295B17.4 64 0.020 rs141601285 
RP11-295B17.2 55 0.022 rs60923396 
TMEM89 10 0.022 rs1264191 
TTC34 62 0.022 C1P2626472 
SLC26A6 11 0.023 rs1264191 
UQCRC1 15 0.026 rs1264191 
NCKIPSD 17 0.028 rs6763557 
ZNF114 167 0.029 rs58249067 
CELSR3 13 0.031 rs13096357 
BSN 27 0.041 rs9836291 
Ulcerative colitis NR5A2 172 1.0 × 10-7 rs2816950 
TMEM8C 99 6.2 × 10-4 rs3094325 
LINC00339 59 9.7 × 10-4 rs3820290 
RP11-594C13.1 147 0.0034 rs76145598 
AZU1P1 20 0.0075 rs9548954 
GS1-259H13.10 23 0.017 rs78680379 
ACER3 69 0.019 rs61902094 
TMEM89 10 0.022 rs1264191 
RP11-295B17.4 67 0.022 rs141601285 
SLC26A6 11 0.023 rs1264191 
UQCRC1 15 0.025 rs1264191 
TTC34 81 0.026 C1P2626472 
27 
 
BANK1 317 0.034 rs76831217 
ITGAL 33 0.041 rs4350585 
BSN 27 0.041 rs9836291 
Crohn’s disease ACTR2 30 2.5 × 10-4 rs268871 
TMEM8C 99 6.0 × 10-4 rs3094325 
RP11-594C13.1 147 0.0034 rs76145598 
SFMBT1 73 0.0039 rs115632241 
RP11-894J14.5 73 0.0041 rs115632241 
rs9491697 b 24 0.0066 rs12525327 
AC007318.5 14 0.0071 rs6741232 
NF2 50 0.012 rs9613968 
PPP3CA 129 0.014 rs756317 
GS1-259H13.10 23 0.017 rs78680379 
ACER3 69 0.019 rs61902094 
RP11-295B17.2 55 0.022 rs60923396 
TMEM89 10 0.022 rs1264191 
SLC26A6 11 0.023d rs1264191 
UQCRC1 15 0.025 rs1264191 
ZNF114 167 0.029 rs58249067 
BSN 27 0.041 rs9836291 
RP1-96H9.5 72 0.046 rs11064124 
Celiac disease CUX2 117 0.014446 rs4766453 
TTC34 86 0.027062 C1P2626472 
IL12A-AS1 201 0.031047 rs73171911 
COX17 39 0.03746 rs6785698 
a The analysis was adjusted for age, sex, study, geographic region, and the top eigenvectors. 












Table 4. Association a of Inflammatory Gastrointestinal Disease SNPs and Risk of PDAC at a P < 0.001 in PanScan and 
PanC4 Studies 
Disease group SNP Gene Chr. Position Alleles b OR (95% CI) P-value 
IBD rs2816950 NR5A2 1 199998491 G/C 0.82 (0.78-0.87) 2.4 × 10-13 
rs268871 ACTR2 2 65481008 C/A 0.88 (0.82-0.93) 2.1 × 10-5 
rs56792073 ACTR2 2 65512340 C/G 0.92 (0.88-0.96) 1.2 × 10-4 
rs72822420 ACTR2 2 65513767 T/C 0.88 (0.82-0.94) 2.0 × 10-4 
rs3820290 LINC00339 1 22333595 A/G 0.91 (0.87-0.96) 1.2 × 10-4 
rs140356857 LINC00339 1 22334151 G/A 0.83 (0.75-0.92) 2.2 × 10-4 
rs60189068 LINC00339 1 22336643 G/C 0.86 (0.80-0.93) 2.2 × 10-4 
rs2501299 LINC00339 1 22345647 T/C 0.92 (0.88-0.96) 6.2 × 10-4 
rs3094325 TMEM8C 9 136360877 A/G 0.78 (0.69-0.88) 3.7 × 10-5 
rs9331726 TMEM8C 9 136368685 T/G 0.79 (0.70-0.89) 8.3 × 10-5 
rs9330459 TMEM8C 9 136371224 T/G 0.79 (0.71-0.89) 8.7 × 10-5 
rs13293068 TMEM8C 9 136379129 T/C 0.78 (0.69-0.89) 1.0 × 10-4 
rs9286382 TMEM8C 9 136383216 T/C 0.78 (0.68-0.88) 1.3 × 10-4 
rs76145598 RP11-594C13.1 14 87951925 A/G 0.73 (0.64-0.85) 1.9 × 10-5 
rs183768453 RP11-594C13.1 14 87959580 A/C 0.75 (0.65-0.87) 1.6 × 10-4 
rs117209303 RP11-594C13.1 14 87942082 G/T 0.76 (0.66-0.88) 2.6 × 10-4 
rs1372993 rs1991866 8 129565662 G/A 0.86 (0.80-0.93) 4.2 × 10-5 
rs16903111 rs1991866 8 129586776 T/C 0.88 (0.83-0.95) 3.7 × 10-4 
rs6741232 AC007318.5 2 65424889 G/A 0.90 (0.85-0.95) 5.2 × 10-4 
rs9548954 AZU1P1 13 40437892 A/G 0.77 (0.66-0.88) 2.0 × 10-4 
rs9532431 COG6 13 40352443 G/A 0.77 (0.67-0.88) 1.1 × 10-4 
rs117960821 COG6 13 40230066 C/T 0.79 (0.70-0.90) 2.6 × 10-4 
rs9613968 NF2 22 29980315 C/T 0.92 (0.88-0.96) 1.4 × 10-4 
rs756317 PPP3CA 4 102147410 T/C 0.90 (0.86-0.95) 2.1 × 10-4 
rs2850958 PPP3CA 4 102171606 G/A 0.88 (0.82-0.94) 2.8 × 10-4 
rs2119601 PPP3CA 4 102173886 C/T 0.89 (0.83-0.95) 8.3 × 10-4 
rs4766453 CUX2 12 111692124 T/C 0.90 (0.86-0.95) 6.8 × 10-5 
rs34067653 F5 1 169469188 T/C 0.92 (0.88-0.96) 2.1 × 10-4 
rs11699483 FERMT1 20 6048460 G/A 0.88 (0.82-0.95) 5.7 × 10-4 
rs62199232 FERMT1 20 6050137 T/G 0.88 (0.82-0.95) 7.5 × 10-4 
rs1884649 FERMT1 20 6047155 G/A 0.88 (0.82-0.95) 7.5 × 10-4 
C1P2626472 TTC34 1 2626472 C/A 0.82 (0.74-0.91) 1.9 × 10-4 
rs58249067 ZNF114 19 48745291 C/T 0.88 (0.82-0.94) 1.4 × 10-4 
rs7252339 ZNF114 19 48784141 A/C 0.92 (0.88-0.97) 8.3 × 10-4 
Ulcerative colitis rs2816950 NR5A2 1 199998491 G/C 0.82 (0.78-0.87) 2.4 × 10-13 
rs3094325 TMEM8C 9 136360877 A/G 0.78 (0.69-0.88) 3.7 × 10-5 
rs9331726 TMEM8C 9 136368685 T/G 0.79 (0.70-0.89) 8.3 × 10-5 
rs9330459 TMEM8C 9 136371224 T/G 0.79 (0.71-0.89) 8.7 × 10-5 
rs13293068 TMEM8C 9 136379129 T/C 0.78 (0.69-0.89) 1.0 × 10-4 
rs9286382 TMEM8C 9 136383216 T/C 0.78 (0.68-0.88) 1.3 × 10-4 
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rs3820290 LINC00339 1 22333595 A/G 0.91 (0.87-0.96) 1.2 × 10-4 
rs140356857 LINC00339 1 22334151 G/A 0.83 (0.75-0.92) 2.2 × 10-4 
rs60189068 LINC00339 1 22336643 G/C 0.86 (0.80-0.93) 2.2 × 10-4 
rs2501299 LINC00339 1 22345647 T/C 0.92 (0.88-0.96) 6.2 × 10-4 
rs76145598 RP11-594C13.1 14 87951925 A/G 0.73 (0.64-0.85) 1.9 × 10-5 
rs183768453 RP11-594C13.1 14 87959580 A/C 0.75 (0.65-0.87) 1.6 × 10-4 
rs117209303 RP11-594C13.1 14 87942082 G/T 0.76 (0.66-0.88) 2.6 × 10-4 
rs9548954 AZU1P1 13 40437892 A/G 0.77 (0.66-0.88) 2.1 × 10-4 
C1P2626472 TTC34 1 2626472 C/A 0.82 (0.74-0.91) 1.9 × 10-4 
rs76831217 BANK1 4 102499219 G/A 0.90 (0.85-0.95) 2.1 × 10-4 
rs2903269 BANK1 4 102450302 T/C 0.91 (0.86-0.96) 2.8 × 10-4 
Crohn’s disease rs268871 ACTR2 2 65481008 C/A 0.88 (0.82-0.93) 2.1 × 10-5 
rs56792073 ACTR2 2 65512340 C/G 0.92 (0.88-0.96) 1.2 × 10-4 
rs72822420 ACTR2 2 65513767 T/C 0.88 (0.82-0.94) 2.0 × 10-4 
rs3094325 TMEM8C 9 136360877 A/G 0.78 (0.69-0.88) 3.7 × 10-5 
rs9331726 TMEM8C 9 136368685 T/G 0.79 (0.70-0.89) 8.3 × 10-5 
rs9330459 TMEM8C 9 136371224 T/G 0.79 (0.71-0.89) 8.7 × 10-5 
rs13293068 TMEM8C 9 136379129 T/C 0.78 (0.69-0.89) 1.0 × 10-4 
rs9286382 TMEM8C 9 136383216 T/C 0.78 (0.68-0.88) 1.3 × 10-4 
rs76145598 RP11-594C13.1 14 87951925 A/G 0.73 (0.64-0.85) 1.9 × 10-5 
rs183768453 RP11-594C13.1 14 87959580 A/C 0.75 (0.65-0.87) 1.6 × 10-4 
rs117209303 RP11-594C13.1 14 87942082 G/T 0.76 (0.66-0.88) 2.6 × 10-4 
rs115632241 SFMBT1 3 53040808 T/C 0.77 (0.68-0.87) 3.1 × 10-5 
rs115632241 RP11-894J14.5 3 53040808 T/C 0.77 (0.68-0.87) 3.1 × 10-5 
rs12525327 rs9491697 6 127107248 G/A 0.91 (0.86-0.95) 1.6 × 10-4 
rs6741232 AC007318.5 2 65424889 G/A 0.90 (0.85-0.95) 5.2 × 10-4 
rs9613968 NF2 22 29980315 C/T 0.92 (0.88-0.96) 1.4 × 10-4 
rs756317 PPP3CA 4 102147410 T/C 0.90 (0.86-0.95) 2.1 × 10-4 
rs2850958 PPP3CA 4 102171606 G/A 0.88 (0.82-0.94) 2.8 × 10-4 
rs2119601 PPP3CA 4 102173886 C/T 0.89 (0.83-0.95) 8.3 × 10-4 
rs58249067 ZNF114 19 48745291 C/T 0.88 (0.82-0.94) 1.4 × 10-4 
rs7252339 ZNF114 19 48784141 A/C 0.92 (0.88-0.97) 8.3 × 10-4 
Celiac disease rs4766453 CUX2 12 111692124 T/C 0.90 (0.86-0.95) 6.8 × 10-5 
C1P2626472 TTC34 1 2626472 C/A 0.82 (0.74-0.91) 1.9 × 10-4 
rs73171911 IL12A-AS1 3 159818194 G/A 0.82 (0.74-0.90) 8.6 × 10-5 
Abbreviations: Chr., chromosome; CI, confidence interval; OR, odds ratio. 
a The analysis was adjusted for age, sex, study, geographic region, and the top eigenvectors. 
b Reference allele/risk allele 
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Supplemental Table 1.  Association a of Inflammatory Gastrointestinal Disease Group 
With Risk of PDAC by Study Design in PanScan and PanC4 Studies 
Study design Disease group Gene, n SNPs, n P-value 
Cohort b Ulcerative colitis 162 13,353 0.84 
Crohn’s disease 263 20,768 0.61 
IBD 350 26,259 0.44 
Celiac disease 40 3,592 0.44 
Case-control c 
 
Ulcerative colitis 163 13,513 0.0055 
Crohn’s disease 266 20,926 0.60 
IBD 353 26,484 0.0094 
Celiac disease 40 3,601 0.15 
a The analysis was adjusted for age, sex, study, geographic region, and the top eigenvectors. 
b Cohort studies include PanScan Ⅰ and PanScan Ⅲ cohort studies. 


















Supplemental Table 2. Association a of Inflammatory Gastrointestinal Disease Gene and 
Risk of PDAC at a P < 0.05 After Excluding the 500kb Region Upstream and Downstream 
of the PDAC GWAS Risk Signals in PanScan and PanC4 Studies 
Disease group Gene No. of SNPs P-value 
Most significant 
SNP 
IBD ACTR2 30 2.4 × 10-4 rs268871 
LINC00339 48 3.3 × 10-4 rs3820290 
RP11-594C13.1 147 0.0034 rs76145598 
AC007318.5 14 0.0070 rs6741232 
AZU1P1 20 0.0075 rs9548954 
COG6 83 0.0082 rs9532431 
NF2 50 0.012 rs9613968 
PPP3CA 129 0.014 rs756317 
CUX2 117 0.014 rs4766453 
F5 50 0.015 rs34067653 
FERMT1 107 0.016 rs11699483 
GS1-259H13.10 23 0.017 rs78680379 
ACER3 69 0.019 rs61902094 
RP11-213G21.2 43 0.019 rs80095830 
RP11-295B17.4 64 0.020 rs141601285 
RP11-295B17.2 55 0.022 rs60923396 
TMEM89 10 0.022 rs1264191 
TTC34 62 0.022 C1P2626472 
SLC26A6 11 0.023 rs1264191 
UQCRC1 15 0.025 rs1264191 
NCKIPSD 17 0.028 rs6763557 
ZNF114 167 0.029 rs58249067 
CELSR3 13 0.031 rs13096357 
BSN 27 0.041 rs9836291 
Ulcerative colitis LINC00339 59 9.8 × 10-4 rs3820290 
RP11-594C13.1 147 0.0035 rs76145598 
AZU1P1 20 0.0075 rs9548954 
GS1-259H13.10 23 0.017 rs78680379 
ACER3 69 0.019 rs61902094 
RP11-295B17.4 67 0.022 rs141601285 
TMEM89 10 0.022 rs1264191 
SLC26A6 11 0.023 rs1264191 
UQCRC1 15 0.025 rs1264191 
TTC34 81 0.026 C1P2626472 
BANK1 317 0.034 rs76831217 
ITGAL 33 0.040 rs4350585 
BSN 27 0.041 rs9836291 
Crohn’s disease ACTR2 30 2.4 × 10-4 rs268871 
32 
 
RP11-594C13.1 147 0.0034 rs76145598 
SFMBT1 73 0.0039 rs115632241 
RP11-894J14.5 73 0.0041 rs115632241 
rs9491697 b 24 0.0066 rs12525327 
AC007318.5 14 0.0071 rs6741232 
NF2 50 0.012 rs9613968 
PPP3CA 129 0.014 rs756317 
GS1-259H13.10 23 0.017 rs78680379 
ACER3 69 0.019 rs61902094 
RP11-295B17.2 55 0.022 rs60923396 
TMEM89 10 0.022 rs1264191 
SLC26A6 11 0.023 rs1264191 
UQCRC1 15 0.025 rs1264191 
ZNF114 167 0.029 rs58249067 
BSN 27 0.041 rs9836291 
RP1-96H9.5 72 0.046 rs11064124 
Celiac disease CUX2 117 0.014 rs4766453 
TTC34 86 0.027 C1P2626472 
IL12A-AS1 201 0.031 rs73171911 
COX17 39 0.038 rs6785698 
a The analysis was adjusted for age, sex, study, geographic region, and the top eigenvectors. 
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